Alnuctamab
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control[2][3].
Product Specifications
CAS Number
2296827-07-9
Product Name Alternative
EM901; CC-93269
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/alnuctamab.html
Purity
99.89
Solubility
10 mM in DMSO
Smiles
[Alnuctamab]
Molecular Weight
(192.13 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cathepsin D (Tumor Marker) (CTSD/3083), 0.2mg/mL
MTCO1 (COX1) (N-term) Rabbit Polyclonal Antibody
(2R,3R,4S,5R)-1,2:4,5-Di-O-isopropylidene-3-nonadecanol
